| Market Cap | 26.80B | P/E | 59.99 | EPS this Y | 6.80% | Ern Qtrly Grth | - |
| Income | 1.02B | Forward P/E | 15.99 | EPS next Y | 7.70% | 50D Avg Chg | -7.00% |
| Sales | 7.39B | PEG | 2.17 | EPS past 5Y | 5.05% | 200D Avg Chg | - |
| Dividend | 1.00% | Price/Book | 2.17 | EPS next 5Y | 6.93% | 52W High Chg | -14.00% |
| Recommedations | 2.60 | Quick Ratio | 0.65 | Shares Outstanding | 205.46M | 52W Low Chg | 25.00% |
| Insider Own | 0.13% | ROA | 4.40% | Shares Float | 204.56M | Beta | 1.02 |
| Inst Own | 91.02% | ROE | 8.36% | Shares Shorted/Prior | 4.25M/4.59M | Price | 128.38 |
| Gross Margin | 71.82% | Profit Margin | 13.85% | Avg. Volume | 1,400,293 | Target Price | 137.17 |
| Oper. Margin | 23.70% | Earnings Date | May 2 | Volume | 2,202,577 | Change | -2.94% |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
| Evercore ISI Group | In-Line | Apr 4, 24 |
| Citigroup | Neutral | Apr 3, 24 |
| Canaccord Genuity | Hold | Feb 23, 24 |
| Barclays | Underweight | Feb 12, 24 |
| Truist Securities | Hold | Feb 9, 24 |
| JP Morgan | Neutral | Feb 9, 24 |
| RBC Capital | Outperform | Feb 9, 24 |
| RBC Capital | Outperform | Jan 12, 24 |
| Evercore ISI Group | In-Line | Jan 4, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MICHELSON MICHAEL W | Director Director | Aug 25 | Buy | 115.500 | 1,300 | 150,150 | 3,385 | 08/29/23 |
| BERNARD BETSY J | Director Director | Mar 20 | Buy | 113.36 | 1,021 | 115,741 | 5,271 | 08/29/23 |
| HIGGINS ARTHUR J | Director Director | Aug 23 | Buy | 115.61 | 1,000 | 115,610 | 3,400 | 08/25/23 |
| Yi Sang | President, Asia Paci.. President, Asia Pacific | Dec 14 | Sell | 124.16 | 2,800 | 347,648 | 5,837 | 12/15/21 |